Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on Ganaxolone for Children and Adults with Epilepsy Related to Tuberous Sclerosis Complex

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Tuberous Sclerosis Complex (TSC)-related epilepsy. TSC is a genetic disorder that causes non-cancerous tumors to form in many different organs, primarily the brain, which can lead to seizures. The treatment being tested in this study is called Ganaxolone, which is a type of medication known as a neurosteroid. Neurosteroids are compounds that can influence brain activity and are being explored for their potential to help manage seizures.

The purpose of this study is to evaluate the long-term safety and tolerability of Ganaxolone when used alongside other treatments for seizures in both children and adults with TSC. Participants in the study will take Ganaxolone in capsule form by mouth. The study will monitor participants over a period to observe any side effects and how well the medication is tolerated. Participants will also continue their usual seizure treatments while taking Ganaxolone.

Throughout the study, various health checks will be conducted, including monitoring vital signs like blood pressure and heart rate, as well as performing physical and neurological exams. The study will also track changes in seizure frequency and assess the overall quality of life for participants. This information will help researchers understand how effective Ganaxolone is in managing seizures associated with TSC and its impact on the daily lives of those affected by this condition.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will have an initial visit where you will be informed about the study's nature and risks. You will be asked to provide written consent to participate. If you are unable to provide consent due to age or other factors, a parent or legal representative will do so on your behalf.

    During this visit, a blood test will be conducted to ensure you are not pregnant if you are a woman of childbearing potential. You will also be asked about your current method of birth control.

  2. Step 2

    Medication administration

    You will begin taking the study medication, ganaxolone, in the form of capsules. The medication is to be taken orally three times a day with food.

    It is important to follow the dosage instructions carefully and maintain a consistent schedule for taking the medication.

  3. Step 3

    Daily seizure diary

    You or your caregiver will be required to keep a daily diary of any seizures you experience. This diary is crucial for tracking the frequency and type of seizures during the study.

  4. Step 4

    Regular check-ups

    Throughout the study, you will have regular check-ups to monitor your health and the effects of the medication. These check-ups will include measurements of vital signs such as blood pressure, heart rate, and body temperature.

    You will also undergo physical, neurological, and developmental examinations, as well as an electrocardiogram (ECG) to check your heart's activity.

  5. Step 5

    Laboratory tests

    Clinical laboratory tests will be conducted periodically to assess your overall health and any potential side effects of the medication.

  6. Step 6

    Safety and tolerability assessment

    The study aims to assess the long-term safety and tolerability of ganaxolone as an additional treatment for seizures associated with tuberous sclerosis complex. Any adverse effects or changes in your condition will be closely monitored.

  7. Step 7

    End of study evaluation

    At the end of the study, a final evaluation will be conducted to assess the overall impact of the treatment on your seizure frequency and quality of life.

    You will be asked to provide feedback on your experience and any changes you have noticed during the study.

Who can join the trial?

6 criteria

  • Must have completed a previous study related to Tuberous Sclerosis Complex (TSC) or continue to meet the requirements of an ongoing study.
  • The participant or their parent(s)/legal representative(s) must be willing and able to provide written consent after understanding the study's nature and risks. If the participant cannot provide consent due to age or other factors, the parent(s) or legal representative(s) must agree to the participant's involvement.
  • Parents or caregivers must be willing and able to keep a detailed daily record of seizures throughout the study.
  • Must be willing and able to take the study medication as a liquid with food three times a day.
  • Women of childbearing potential must use a medically approved method of birth control and have a negative pregnancy test at the start of the study. Childbearing potential refers to females who can become pregnant. Acceptable birth control methods include devices placed inside the body, hormonal methods like pills or patches, and surgical procedures to prevent pregnancy.
  • Male participants must agree to use highly effective birth control methods during the study and for 30 days after the last dose of the study medication. This includes surgical procedures like a vasectomy or using two forms of barrier protection.

Who cannot join the trial?

8 criteria

  • Patients who do not have **Tuberous Sclerosis Complex (TSC)** related epilepsy cannot participate. TSC is a genetic disorder that causes non-cancerous tumors to form in many different organs.
  • Patients who are not experiencing seizures associated with TSC cannot participate. Seizures are sudden, uncontrolled electrical disturbances in the brain.
  • Patients who are not within the specified age range for the study cannot participate. The study includes children and adults.
  • Patients who are not able to take the study medication safely cannot participate. This means if the medication could cause harm or serious side effects, the patient cannot join.
  • Patients who are pregnant or breastfeeding cannot participate. This is to ensure the safety of both the mother and the baby.
  • Patients who are participating in another clinical trial cannot participate. This is to avoid any interference with the study results.
  • Patients who have a history of drug or alcohol abuse cannot participate. This is to ensure the safety and accuracy of the study results.
  • Patients who have a serious medical condition that could interfere with the study cannot participate. This includes conditions that might make it unsafe for the patient to take part.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ganaxolone (GNX) is a medication being studied for its potential to help people with epilepsy related to Tuberous Sclerosis Complex (TSC). It is used as an additional treatment to help control seizures. Ganaxolone works by calming the brain's activity, which can help reduce the number of seizures a person experiences. This study is focused on understanding how safe and tolerable Ganaxolone is when used over a long period in both children and adults with TSC-related epilepsy.

What is already known about the treatment

Ganaxolone – Ganaxolone is administered orally and is being studied as an additional treatment for epilepsy related to Tuberous Sclerosis Complex (TSC) in both children and adults. Currently, it is in a Phase 3 clinical trial, which means it is being tested for safety and effectiveness in a larger group of people. The main therapeutic use of Ganaxolone is to help control seizures associated with TSC. At the molecular level, Ganaxolone works by enhancing the activity of a neurotransmitter called GABA, which helps calm down overactive brain activity that can lead to seizures. It is classified as a neuroactive steroid and acts as a positive allosteric modulator of the GABA-A receptor.

Investigated diseases

Tuberous Sclerosis Complex (TSC) related epilepsy – Tuberous Sclerosis Complex is a genetic disorder that causes non-cancerous tumors to form in many different organs, primarily the brain, eyes, heart, kidney, skin, and lungs. When these tumors affect the brain, they can lead to epilepsy, which is characterized by recurrent seizures. The seizures in TSC-related epilepsy can vary in type and severity, including focal seizures, which affect one part of the brain, and generalized seizures, which affect the whole brain. Over time, the frequency and intensity of seizures can change, potentially impacting cognitive and developmental functions. The progression of epilepsy in TSC is influenced by the location and size of the brain lesions. Managing the condition often involves monitoring and adjusting to the evolving nature of the seizures.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-503067-15-00Protocol code1042-TSC-3002Estimated enrolment166 patientsSponsorMarinus Pharmaceuticals Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.